Laura J Zitella, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 29 years
- Graduated 1997
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Laura J Zitella’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$64,883
Medicare paid this office $64,883 for 206 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 160 | $46,745 | $102 |
| Return visit (30+ min) | 57 | $5,511 | $69 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 111 | $2,478 | $13 |
| Short return visit (20+ min) | 21 | $1,099 | $48 |
Procedures year by year
| Procedure | 2017 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | – | 16 | 31 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
206 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 11% · Women 44% · Also on Medicaid 16% · Health risk score 2.60. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 64% · Chronic kidney disease 34% · Diabetes 22% · Coronary heart disease 21% · Atrial fibrillation 18% · Heart failure 16% · Cancer 16% · Depression 15% · COPD 14% · Stroke 7% · Dementia 6%.
The office billed $489,190, Medicare allowed $86,432 and paid $64,883; for 991 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 206 | 991 | 75 | 2.60 | $489,190 | $64,883 |
| 2023 | 169 | 642 | 75 | 2.85 | $433,645 | $58,327 |
| 2022 | 145 | 493 | 72 | 3.11 | $353,788 | $48,424 |
| 2021 | 161 | 471 | 72 | 3.31 | $358,830 | $47,892 |
| 2020 | 51 | 72 | 72 | 2.94 | $57,023 | $5,216 |
| 2017 | 12 | 16 | 67 | 1.54 | $37,636 | $774 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 133 | $48,393 | $107 |
| Return visit (30+ min) | 39 | $3,850 | $69 |
| Short return visit (20+ min) | 11 | $554 | $46 |
2022: 2 services
| Long return visit (40+ min) | 124 | $44,353 | $105 |
| Return visit (30+ min) | 27 | $2,833 | $75 |
2021: 3 services
| Long return visit (40+ min) | 120 | $43,435 | $111 |
| Return visit (30+ min) | 23 | $1,988 | $71 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 31 | $1,804 | $58 |
2020: 2 services
| Long return visit (40+ min) | 29 | $3,846 | $80 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | $1,004 | $63 |
Drugs they prescribed that Part D paid
$1,307,103
Pharmacies billed $1,307,103 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (14 of 679) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
550 generic and fewer than 11 brand-name prescriptions · $1,307,103 in drug cost · 75 antibiotic prescriptions to 37 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 42 | $553,798 | $13,186 |
| Imbruvica | 31 | $489,351 | $15,786 |
| Eliquis | 14 | $18,335 | $1,310 |
| Atovaquone | 23 | $13,446 | $585 |
| Entecavir | 13 | $6,306 | $485 |
See all 16 drugs
| Brukinsa | 42 | $553,798 | $13,186 |
| Imbruvica | 31 | $489,351 | $15,786 |
| Eliquis | 14 | $18,335 | $1,310 |
| Atovaquone | 23 | $13,446 | $585 |
| Entecavir | 13 | $6,306 | $485 |
| Valacyclovir | 54 | $2,789 | $52 |
| Acyclovir | 70 | $2,173 | $31 |
| Gabapentin | 25 | $329 | $13 |
| Ondansetron | 13 | $317 | $24 |
| Famotidine | 16 | $281 | $18 |
| Sulfamethoxazole-Trimethoprim | 33 | $215 | $7 |
| Allopurinol | 19 | $158 | $8 |
| Trazodone | 11 | $114 | $10 |
| Prednisone | 21 | $78 | $4 |
| Levofloxacin | 11 | $73 | $7 |
| Pantoprazole | 13 | $66 | $5 |
Year by year
| 2024 | 679 | 141 | 2% (14) | None | $1,307,103 |
| 2023 | 701 | 163 | 5% (36) | None | $1,656,651 |
| 2022 | 589 | 128 | 5% (32) | None | $1,268,149 |
| 2021 | 337 | 68 | 6% (20) | 8% | $134,270 |
| 2020 | 24 | 12 | None | None | $2,599 |
| 2018 | 17 | 12 | None | None | $552 |
| 2017 | 110 | 34 | None | None | $126,211 |
| 2016 | 73 | 20 | None | 25% | $58,251 |
| 2015 | 17 | None | 0% (0) | None | $541 |
| 2014 | 55 | 16 | None | None | $7,461 |
| 2013 | 100 | 22 | 13% (13) | 16% | $17,869 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Brukinsa | 45 | $583,671 | $12,970 |
| Imbruvica | 36 | $581,863 | $16,163 |
| Calquence | 12 | $191,549 | $15,962 |
| Atovaquone | 22 | $16,597 | $754 |
| Entecavir | 24 | $7,847 | $327 |
| Valacyclovir | 45 | $3,024 | $67 |
| Acyclovir | 99 | $2,439 | $25 |
| Gabapentin | 25 | $593 | $24 |
| Sulfamethoxazole-Trimethoprim | 53 | $583 | $11 |
| Allopurinol | 18 | $168 | $9 |
| Levofloxacin | 17 | $142 | $8 |
| Famotidine | 17 | $111 | $7 |
| Lorazepam | 11 | $58 | $5 |
2022: 17 drugs
| Brukinsa | 32 | $418,429 | $13,076 |
| Iclusig | 12 | $258,216 | $21,518 |
| Calquence | 13 | $187,097 | $14,392 |
| Imbruvica | 11 | $154,503 | $14,046 |
| Atovaquone | 21 | $18,151 | $864 |
| Eliquis | 11 | $7,227 | $657 |
| Acyclovir | 67 | $1,927 | $29 |
| Valacyclovir | 29 | $1,521 | $52 |
| Entecavir | 19 | $1,302 | $69 |
| Gabapentin | 17 | $292 | $17 |
| Sulfamethoxazole-Trimethoprim | 52 | $287 | $6 |
| Oxycodone | 19 | $284 | $15 |
| Famotidine | 11 | $269 | $24 |
| Ondansetron | 14 | $202 | $14 |
| Olanzapine | 13 | $197 | $15 |
| Allopurinol | 16 | $174 | $11 |
| Atorvastatin | 17 | $133 | $8 |
2021: 7 drugs
| Acyclovir | 20 | $533 | $27 |
| Potassium Chloride | 16 | $522 | $33 |
| Dexamethasone | 16 | $503 | $31 |
| Famotidine | 14 | $196 | $14 |
| Olanzapine | 11 | $112 | $10 |
| Prednisone | 20 | $106 | $5 |
| Sulfamethoxazole-Trimethoprim | 22 | $98 | $4 |
Money from drug and device companies
$2,795 in 2025
| 2025 | 8 | 10 | $2,250 | $2,795 |
| 2024 | 3 | 7 | $150 | $698 |
| 2023 | 4 | 5 | $1,050 | $1,164 |
| 2022 | 3 | 4 | $3,475 | $3,650 |
| 2021 | 1 | 1 | None | $99 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $1,200 | 1 payment
|
| Pfizer | Elrexfio | $1,050 | 2 payments
|
| Abbvie | Venclexta | $136 | 2 payments
|
| Janssen Biotech | Tecvayli | $125 | 1 payment
|
| Genzyme | Sarclisa | $109 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $83 | 1 payment
|
See all 10 published payments
| Janssen Biotech | Meals · 2025-11-22 | Tecvayli | $125 |
| Abbvie | Meals · 2025-11-22 | Venclexta | $116 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-10-29 | None | $1,200 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-24 | None | $83 |
| Genzyme | Meals · 2025-10-23 | Sarclisa | $109 |
| Pfizer | Consulting · 2025-08-20 | Elrexfio | $300 |
| Pfizer | Consulting · 2025-08-14 | Elrexfio | $750 |
| Abbvie | Meals · 2025-01-30 | Imbruvica | $21 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-25 | Onivyde | $76 |
| Adaptive Biotechnologies | Meals · 2025-01-16 | Clonoseq | $17 |
See earlier years (2024, 2023, 2022, 2021)
2024: $698
| Abbvie | Epkinly | $327 | 4 payments
|
| BeiGene USA | Brukinsa | $257 | 2 payments
|
| Janssen Biotech | Tecvayli | $114 | 1 payment
|
2023: $1,164
| BeiGene USA | Brukinsa | $1,050 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $47 | 2 payments
|
| Janssen Scientific Affairs | Erleada | $44 | 1 payment
|
| Kyowa Kirin | Poteligeo | $24 | 1 payment
|
2022: $3,650
| Abbvie | Venclexta | $2,475 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,000 | 1 payment
|
| Janssen Biotech | Darzalex | $175 | 2 payments
|
2021: $99
| Incyte | None | $99 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1265570949
- Licence
- CA NP10563
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LA2100X (363LA2100X); Nurse practitioner (363L00000X)
- Mailing address
- 875 Blake Wilbur Dr, Mail Code 5820, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-02
- NPI last updated
- 2026-04-27
- NPI record certified
- 2026-04-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305